Post by
SPCEO1 on Sep 23, 2021 10:48am
Another analyst just mailing it in
Canaccord came out with a report on the IV Push news and it just rehashed the press release and added no value. Worse, it ended with this aggregious, if unimportant, error, " Net sales of Trogarzo were $7.4M in 2Q21,representing 13% of the company’s total worldwide net sales for 2Q21."
I wish that were actually true as it would indicate TH had total second quarter sales of $57 million! It is hard to see how Ed Nash did not quickly catch this.
Once again, it is a odd error to make but insignificant. What it highlights is we need analysts covering the stock who are both very good at what they do and are fully awake while writing their research reports. Ed is pretty good at what he does but must not have had his coffee yet when writing this note.
Comment by
Wino115 on Sep 23, 2021 12:04pm
I can smell the Cheetos on that one...
Comment by
SPCEO1 on Sep 23, 2021 12:39pm
I should havhe also mentioned that Ed Nash, a NASH expert, wasted 10 minutes on producing that note on the new IV Push formulation but, like NBF's analyst, spent exactly zero minutes addressing the fact that the NASH industry's two leading experts endorsed Egrifta's phase III NASH trial. Talk about missing the forest for the trees....